Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jun 09, 2022

Notice of Filing an Appeal in Patent Infringement Lawsuit concerning Edirol Capsule

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.
Tel:+81-(0)3-3273-0554

Chugai Pharmaceutical Co., Ltd. announced that Chugai has appealed today to the Intellectual Property High Court of the patent infringement lawsuit regarding the generic drugs to an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule) that was notified in the “Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules” dated May 27, 2022.

  1. The Court and Date of Appeal
    The Intellectual Property High Court, June 9, 2022
  2. Reasons for the Appeal

    As Chugai announced in the “Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules” dated May 27, 2022, the Tokyo District Court rendered judgment to dismiss the plaintiff’s claim in the lawsuit filed by Chugai on May 29, 2020 against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. After consideration of the written judgment in detail, Chugai has determined to appeal the Tokyo District Court’s decision.

  3. Defendants
    1. Name: Sawai Pharmaceutical Co., Ltd.
      Address: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
    2. Name: Nichi-Iko Pharmaceutical Co., Ltd.
      Address: 1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan
  4. Prospects
    No changes are expected to Chugai’s financial prospects at this point.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top